Treatment of Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Systemic Therapy.
作者信息
Khilwani Harsh, Stettner Sarah, Sonnabend Kyle, Chen Yolande, Jain Shikha, Gaba Ron C
机构信息
University of Illinois College of Medicine, Chicago, Illinois.
Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
出版信息
Semin Intervent Radiol. 2024 Aug 19;41(3):309-316. doi: 10.1055/s-0044-1787835. eCollection 2024 Jun.
Abstract
摘要
相似文献
1
Treatment of Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Systemic Therapy.经动脉化疗栓塞联合全身治疗肝细胞癌
Semin Intervent Radiol. 2024 Aug 19;41(3):309-316. doi: 10.1055/s-0044-1787835. eCollection 2024 Jun.
2
Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial.三氧化二砷经动脉化疗栓塞联合或不联合额外静脉注射三氧化二砷治疗不可切除的伴有肺转移的肝细胞癌：一项单盲随机试验
J Cancer Res Clin Oncol. 2015 Jun;141(6):1103-8. doi: 10.1007/s00432-014-1866-1. Epub 2014 Dec 14.
3
Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study.经动脉化疗栓塞联合动脉内输注信迪利单抗和贝伐单抗治疗晚期肝细胞癌：一项2期研究。
Cancer Lett. 2025 Sep 28;628:217851. doi: 10.1016/j.canlet.2025.217851. Epub 2025 Jun 3.
4
Transarterial chemoembolization combined with lenvatinib transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.经动脉化疗栓塞联合乐伐替尼与经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的系统评价和荟萃分析
World J Gastrointest Oncol. 2025 Jun 15;17(6):105887. doi: 10.4251/wjgo.v17.i6.105887.
5
Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis.乐伐替尼联合经动脉化疗栓塞术（伴或不伴程序性死亡-1抑制剂）治疗中晚期肝细胞癌的疗效和安全性：一项系统评价和荟萃分析
Front Immunol. 2025 Jul 24;16:1586914. doi: 10.3389/fimmu.2025.1586914. eCollection 2025.
6
Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.立体定向体部放疗联合与不联合经动脉化疗栓塞与单纯经动脉化疗栓塞治疗早期肝细胞癌的系统评价和荟萃分析。
J Gastrointest Cancer. 2023 Dec;54(4):1058-1070. doi: 10.1007/s12029-023-00940-5. Epub 2023 Jun 12.
7
Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization.索拉非尼联合载药微球经动脉化疗栓塞术治疗常规经动脉化疗栓塞术难治的早期肝内进展期晚期肝细胞癌
J Cancer Res Clin Oncol. 2023 May;149(5):1873-1882. doi: 10.1007/s00432-022-04107-w. Epub 2022 Jul 5.
8
Balloon-occluded versus conventional transarterial chemoembolization for the treatment of early to intermediate stage hepatocellular carcinoma: a meta-analysis and trial sequential analysis.球囊闭塞与传统经动脉化疗栓塞治疗早期至中期肝细胞癌的Meta分析和试验序贯分析
BMC Cancer. 2025 Jul 1;25(1):1036. doi: 10.1186/s12885-025-14435-y.
9
Transarterial Radioembolization with Yttrium-90 and SIRT Versus Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.钇-90经动脉放射性栓塞术和选择性体内放射治疗与传统经动脉化疗栓塞术治疗肝细胞癌的系统评价和Meta分析
Acad Radiol. 2025 Jun 27. doi: 10.1016/j.acra.2025.06.008.
10
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.中期肝细胞癌患者的管理：一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD011649. doi: 10.1002/14651858.CD011649.pub2.
本文引用的文献
1
SIRT in 2025.SIRT 在 2025 年。
Cardiovasc Intervent Radiol. 2022 Nov;45(11):1622-1633. doi: 10.1007/s00270-022-03228-6. Epub 2022 Aug 8.
2
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).仑伐替尼联合经动脉化疗栓塞术作为晚期肝细胞癌一线治疗的III期随机临床试验（LAUNCH）
J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3.
3
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.索拉非尼和仑伐替尼作为一线系统治疗乙型肝炎相关肝细胞癌的疗效比较：倾向评分匹配分析。
BMC Gastroenterol. 2022 Mar 25;22(1):135. doi: 10.1186/s12876-022-02210-3.
4
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.随机 3 期 LEAP-012 研究：经动脉化疗栓塞联合或不联合仑伐替尼加帕博利珠单抗治疗不可治愈的中期肝细胞癌。
Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4.
5
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.阿替利珠单抗联合贝伐珠单抗与经动脉化疗栓塞治疗肝细胞癌：DEMAND 试验方案。
Future Oncol. 2022 Apr;18(12):1423-1435. doi: 10.2217/fon-2021-1261. Epub 2022 Jan 27.
6
Recent advances in systemic therapy for hepatocellular carcinoma.肝细胞癌全身治疗的最新进展
Biomark Res. 2022 Jan 9;10(1):3. doi: 10.1186/s40364-021-00350-4.
7
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
8
In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?在肝细胞癌系统治疗时代，经动脉化疗栓塞术仍是一张可打的牌吗？
Cancers (Basel). 2021 Oct 13;13(20):5129. doi: 10.3390/cancers13205129.
9
Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma.缺氧诱导因子对肝癌索拉非尼耐药性的影响
Front Oncol. 2021 Jul 7;11:641522. doi: 10.3389/fonc.2021.641522. eCollection 2021.
10
Experience with regorafenib in the treatment of hepatocellular carcinoma.瑞戈非尼治疗肝细胞癌的经验
Therap Adv Gastroenterol. 2021 May 28;14:17562848211016959. doi: 10.1177/17562848211016959. eCollection 2021.
Zotero 插件